News
PAVMW
0.0290
-3.33%
-0.0010
PAVmed Inc. Redeems All Outstanding Convertible Securities and Converts Preferred Shares in Major Capital Structure Overhaul
Reuters · 2d ago
PAVmed tilgt ausstehende Wandelanleihen und Vorzugsaktien
Reuters · 2d ago
PAVmed Issues Warrants Linked to $30 Million Series D Preferred Stock Offering
Reuters · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Teledyne, Arm Holdings, Nathan’s Famous
Reuters · 01/21 14:25
BUZZ-Lucid Diagnostics rises after winning VA contract for cancer test
Reuters · 01/21 13:29
LUCID DIAGNOSTICS AWARDED U.S. DEPARTMENT OF VETERANS AFFAIRS CONTRACT FOR ESOGUARD®
Reuters · 01/21 13:01
PAVMED INC - REVERSE STOCK SPLIT EFFECTIVE JANUARY 2, 2026
Reuters · 12/30/2025 14:01
PAVMED INC <PAVM.O>: ASCENDIANT CAPITAL MARKETS CUTS TARGET PRICE TO $17 FROM $20
Reuters · 12/10/2025 08:33
PAVmed Shareholders Approve Reverse Stock Split and Share Reduction
Reuters · 12/05/2025 21:16
PAVMED INC - QTRLY SHR LOSS $0.29
Reuters · 11/12/2025 22:36
PAVmed Inc. to Report Third Quarter 2025 Financial Results
Reuters · 10/30/2025 12:03
Lucid Diagnostics Inc. Files Initial Beneficial Ownership Statement for Director John R. Palumbo
Reuters · 10/07/2025 20:46
PAVmed Subsidiary Veris Health Launches Commercial Phase of Strategic Partnership with Ohio State University Comprehensive Cancer Center
Reuters · 10/07/2025 12:03
PAVMED SUBSIDIARY, VERIS HEALTH AND THE OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER LAUNCH COMMERCIAL PHASE OF STRATEGIC PARTNERSHIP AGREEMENT
Reuters · 10/07/2025 12:02
Lucid Diagnostics Inc. Files Prospectus Supplement for Common Stock Offering, Raising Approximately $26.9 Million
Reuters · 09/11/2025 13:28
BUZZ-Lucid Diagnostics slides on $25 mln stock sale
Reuters · 09/10/2025 12:29
Dennis Matheis, Director, Reports Acquisition of Common Shares in Lucid Diagnostics Inc
Reuters · 08/22/2025 21:18
PAVmed Inc. Reports Q2 2025 Results: Revenue at $1.2 Million, GAAP Net Loss of $13.3 Million, EPS at $(0.74); Adjusted Loss at $1.8 Million, EPS at $(0.11)
Reuters · 08/14/2025 12:03
Lucid Diagnostics Inc reports results for the quarter ended June 30 - Earnings Summary
Reuters · 08/13/2025 13:32
Lucid Diagnostics Inc. Reports Q2 2025 Revenue of $1.2 Million, Processing 2,756 EsoGuard Tests
Reuters · 08/13/2025 12:01
More
Webull provides a variety of real-time PAVMW stock news. You can receive the latest news about Pavmed through multiple platforms. This information may help you make smarter investment decisions.
About PAVMW
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.